Associated equity: Avalo Therapeutics
Edison Investment Research is terminating coverage on Avalo Therapeutics. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
Avalo Therapeutics — 1 video in collection
Avalo is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in the areas of immunology, immuno-oncology and rare disease.
• Tell us about the company.
• How many programmes are you running at the moment?
• Which programmes should investors be focusing on?
• What is the unmet medical need in Crohn’s disease and how is Avalo different in this market?
• How large do you think the Crohn’s market is?
• Tell us about the recent encouraging data on Crohn’s disease.
• Is there a possibility that some people could become refractory to your drug?
• Which milestones should investors focus on in the coming year?
• Please tell us more about your close association with the Children’s Hospital of Philadelphia.